Navigation Links
Researchers Discover All-Natural Weapon In The War Against Ovarian Cancer
Date:8/2/2012

BLAUVELT, N.Y., Aug. 2, 2012 /PRNewswire-iReach/ -- A study published in the International Journal of Gynecological Cancer shows that fermented wheat germ extract (FWGE) is effective in killing a wide range of ovarian cancer cells while simultaneously enhancing the cancer-fighting qualities of certain chemotherapy treatments. Previous human clinical studies with FWGE have shown it can significantly improve survival in melanoma, colorectal and oral cancer patients and lessen the side effects of chemotherapy in pediatric cancer patients.

Lead author of the study is Patricia Judson, MD, gynecologic oncologist and researcher at Moffitt Cancer Center in Tampa, Florida's only National Cancer Institute-designated comprehensive cancer center. Having published more than 40 research articles that have examined standards of cancer treatments including radiation and chemotherapy, Judson says she is most excited about the promise fermented wheat germ extract has shown.

"The results of this study greatly exceeded my expectations," said Dr. Judson. "We have proven that Avemar (FWGE) has the ability to kill cancer cells in the petri dish, and that it enhances the effectiveness of chemotherapy treatments." Judson expressed gratitude to the Moffitt Cancer Center Merit Society for funding this study, and said she is actively seeking grants to underwrite the next stage in Avemar research, which will be ovarian cancer trials in animals and ultimately humans.

The study, which had 13 contributors, reinforces and expands upon prior published research that has shown the potential of fermented wheat germ extract as a non-toxic, cancer-fighting agent. According to the study, the team's findings "confirm the value of Avemar - fermented wheat germ extract (FWGE) - as a natural product with anticancer properties that also enhances the activity of existing therapeutic agents. Furthermore, our findings provide substantial insights into the molecular basis of FWGE's effect on human cancer cells."

FWGE was invented by Hungarian biochemist Mate Hidvegi, Ph.D., and has been the subject of more than 100 international experiments on three continents, and more than 30 peer-reviewed articles. Since inventing this all-natural nutraceutical in the early 1990s, Hidvegi has worked to advance the therapeutic potential for patients diagnosed with a variety of cancers. Previous human clinical studies with Avemar have shown it can significantly improve survival in melanoma, colorectal and oral cancer patients and can lessen the side effects of chemotherapy in pediatric cancer patients.

The patented product is manufactured by American BioSciences, Blauvelt, NY. Further research and drug development on fermented wheat germ extract is sponsored by MSC BioTarget, a New York-based biotech firm. If you are interested in interviewing the principals and learning more about this research, please contact Rick Jahnke, MSC BioTarget LLC, ph: 201-788-4963, email: rjahnkemscbio@gmail.com

CONTACT: Rick Jahnke, MSC BioTarget LLC
Email: rjahnkemscbio@gmail.com
Phone: (201) 788-4963

Media Contact: Rick Jahnke MSC BioTarget LLC, 201-788-4963, rjahnkemscbio@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE MSC BioTarget LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally
2. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
3. Researchers Evaluate Computer-based Treatment for People with Schizophrenia
4. Van Andel Institute Researchers Find Potential Drug Target For Aggressive Form Of Lymphoma
5. Rethinking Research Ethics: Carnegie Mellon and McGill Researchers Challenge Post-marketing Trial Practices
6. Omeros Announces Discovery in MASP-2 Program
7. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
8. Discovery Labs Receives US Patent for Method to Promote Mucus Clearance with Pulmonary Surfactant
9. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
10. Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
11. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... VALLEY COTTAGE, New York , May 31, 2016 ... traction as an essential ingredient in food, cosmetics and ... 2016 end, representing revenues worth US$ 1.6 Bn. ... vera gels, cosmetics products, juices, and yogurts will continue ... health and wellness trend will also boost positive sentiment ...
(Date:5/31/2016)... May 31, 2016 , Isansys  Lifecare, ... its Patient Status Engine wireless patient monitoring platform, as it ... Germany , Scotland and ... 2 nd generation system, launched earlier this year, is now ... , , This new technology significantly enhances ...
(Date:5/30/2016)... , May 30, 2016 ... report "Healthcare Biometrics Market by Technology (Single-factor ... Multifactor, Multimodal), Application (Workforce Management), End User ... 2021", published by MarketsandMarkets, the market is ... 2021 from USD 1,182.6 Million by 2016, ...
Breaking Medicine Technology:
(Date:5/31/2016)... , ... May 31, 2016 ... ... healthcare that considers individuals’ genetic characteristics and the physical and behavioral worlds ... work in sync. In personalized medicine, diagnosing an individual’s disease depends on ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... today announced it has been included by Gartner, Inc. in the Contact Center ... range of Contact Center Infrastructure technologies, some of which include: Computer-telephony integration ...
(Date:5/31/2016)... ... 2016 , ... Twenty years ago it was revolutionary: enabling the people who ... voices they hear. But this approach has proven transformative, both for people who hear ... credibility and now is used around the world, but it still lags in the ...
(Date:5/31/2016)... ... ... DDL, Inc. announced today it has expanded the scope of its ISO/IEC ... and ISO 594-2 testing for conical (Luer) fittings. , A conical Luer fitting ... (e.g. a syringe and hypodermic needle) that carry small volumes of fluids. There are ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only ... the industry as a whole. On June 2, Northbound CEO Mike Neatherton and COO ... (WCSAD) and presenting the opening plenary on “Leadership: The Journey to Authenticity” with Onsite ...
Breaking Medicine News(10 mins):